Ajanta Pharma Ltd banner

Ajanta Pharma Ltd
NSE:AJANTPHARM

Watchlist Manager
Ajanta Pharma Ltd Logo
Ajanta Pharma Ltd
NSE:AJANTPHARM
Watchlist
Price: 2 782.7 INR 0.07% Market Closed
Market Cap: ₹347.7B

Ajanta Pharma Ltd
Total Current Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Ajanta Pharma Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Ajanta Pharma Ltd
NSE:AJANTPHARM
Total Current Assets
₹33.9B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
16%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Current Assets
₹279.6B
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Current Assets
₹249.2B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
11%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Current Assets
₹601.4B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
7%
Lupin Ltd
NSE:LUPIN
Total Current Assets
₹202.7B
CAGR 3-Years
20%
CAGR 5-Years
9%
CAGR 10-Years
9%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Current Assets
₹61.7B
CAGR 3-Years
8%
CAGR 5-Years
2%
CAGR 10-Years
2%
No Stocks Found

Ajanta Pharma Ltd
Glance View

In the bustling landscape of the Indian pharmaceutical industry, Ajanta Pharma Ltd. has carved a niche for itself with a blend of strategic innovation and market smartness. Founded in 1973, the company swiftly harnessed the dynamics of a growing market by focusing on specialty therapeutic segments including cardiology, dermatology, ophthalmology, and pain management. With a distinctive approach that merges global aspirations with local market insights, Ajanta Pharma has established itself as a significant player not just in India, but also across over 30 countries. The company's success is driven by its sustained emphasis on research and development, which fuels its capabilities to roll out new, affordable formulations addressing unmet medical needs. Ajanta Pharma’s business model thrives on a two-pronged strategy: focusing on high-growth emerging markets and capitalizing on the constantly evolving healthcare demands in regulated markets like the United States. The company's adeptness at manufacturing efficiency and its vertically integrated operations enable it to maintain competitive cost structures, delivering value through robust margins. The revenue streams are further amplified by its prowess in developing generic drugs for the American market, where it navigates through complex regulatory landscapes to outpace competitors. Underpinned by a strong commitment to quality and patient-centric innovation, Ajanta Pharma’s operations exemplify a balanced growth trajectory, reinforcing its status as a dynamic and responsive healthcare entity.

AJANTPHARM Intrinsic Value
1 965.18 INR
Overvaluation 29%
Intrinsic Value
Price ₹2 782.7

See Also

What is Ajanta Pharma Ltd's Total Current Assets?
Total Current Assets
33.9B INR

Based on the financial report for Dec 31, 2025, Ajanta Pharma Ltd's Total Current Assets amounts to 33.9B INR.

What is Ajanta Pharma Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
16%

Over the last year, the Total Current Assets growth was 22%. The average annual Total Current Assets growth rates for Ajanta Pharma Ltd have been 9% over the past three years , 11% over the past five years , and 16% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett